Advances in the pharmacological management of acute myeloid leukemia in adults

Keyphrases

• Pharmacological Management 100%
• Acute Myeloid Leukemia 100%
• Metabolic Pathway 20%
• Molecular Pathways 20%
• Tumor Protein p53 (TP53) 20%
• Secondary Acute Myeloid Leukemia (sAML) 20%
• Cellular Products 10%
• Apoptosis 10%
• Area Cover 10%
• Overall Survival 10%
• Macrophages 10%
• Unmet 10%
• Activating mutation 10%
• Leukemia Patients 10%
• Therapeutic Modalities 10%
• Differentiation Block 10%
• Cell Targeting 10%
• B-cell Lymphoma 2 (Bcl-2) 10%
• Chimeric Antigen Receptor T Cells (CAR-T) 10%
• Ongoing Clinical Trials 10%
• Expert Opinion 10%
• Tyrosine Kinase 10%
• IDH mutation 10%
• Leukemia Cells 10%
• Cluster of Differentiation 47 (CD47) 10%
• Limited Treatment Options 10%
• Myeloid Neoplasms 10%
• Molecular Medicine 10%
• FMS-like Tyrosine Kinase 3 (FLT3) 10%
• MLL-rearranged Leukemia 10%
• Precision Approach 10%
• Menin Inhibitors 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Acute Myeloid Leukemia 100%
• Leukemia 20%
• Secondary Acute Myeloid Leukemia 20%
• Preclinical Study 10%
• Clinical Trial 10%
• Receptor 10%
• Overall Survival 10%
• Protein Tyrosine Kinase 10%
• Methionine 10%
• Neoplasm 10%